Skip to main content
SpringerLink
Log in

Phenytoin poisoning

  • Perspectives In Intoxications
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Phenytoin toxicity may result from intentional overdose, dosage adjustments, drug interactions, or alterations in physiology. Intoxication manifests predominantly as nausea, central nervous system dysfunction (particularly confusion, nystagmus, and ataxia), with depressed conscious state, coma, and seizures occurring in more severe cases. Cardiac complications such as arrhythmias and hypotension are rare in cases of phenytoin ingestion, but they may be seen in parenteral administration of phenytoin or fosphenytoin. Deaths are unlikely after phenytoin intoxication alone. A greatly increased half-life in overdose due to zero-order pharmacokinetics can result in a prolonged duration of symptoms and thus prolonged hospitalization with its attendant complications. The mainstay of therapy for a patient with phenytoin intoxication is supportive care. Treatment includes attention to vital functions, management of nausea and vomiting, and prevention of injuries due to confusion and ataxia. There is no antidote, and there is no evidence that any method of gastrointestinal decontamination or enhanced elimination improves outcome.

Activated charcoal should be considered if the patient presents early; however, the role of multiple-dose activated charcoal is controversial. Experimental studies have proven increased clearance rates, but this effect has not been translated into clinical benefit. There is no evidence that any invasive method of enhanced elimination (such as plasmapheresis, hemodialysis, or hemoperfusion) provides any benefit. This article provides an overview of phenytoin pharmacokinetics and the clinical manifestations of toxicity, followed by a detailed review of the various treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Watson W, Litovitz T, Rodgers G, et al. 2002 Annual Report of the American Association of Poison Control Centres Toxic Exposure Surveillance System. Am J Emerg Med. 2003;21:353–421.

    Article  Google Scholar 

  2. Victorian Poisons Information Centre. Annual Report 2002. Accessed at www.rch.unimelb.edu.au/emplibrary/poisons/annrep02.pdf.

  3. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limberd LE, Gilman AG, eds. Goodman and Gilman’s pharmacological basis of therapeutics, 10th ed. New York: McGraw Hill, 2001:521–547.

    Google Scholar 

  4. Tiller JWG, Birkett D, Burns R, et al. Therapeutic guidelines: neurology. Antiepileptics: phenytoin and fosphenytoin. Therapeutic Guidelines, Ltd.: North Melbourne, Victoria, Australia, 2002:4–5.

    Google Scholar 

  5. Woo E, Greenblatt J. Choosing the right phenytoin dosage. Drug Ther 1977;7:131–139.

    Google Scholar 

  6. Grunze H, Walden J. Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder. J Affect Disord 2002;72 (Suppl 1):S15-S21.

    Article  PubMed  CAS  Google Scholar 

  7. Atkinson AJ Jr, Davison R. Diphenylhydantoin as an antiarrhythmic drug. Annu Rev Med 1974;25:99–113.

    Article  PubMed  CAS  Google Scholar 

  8. Seger D. Phenytoin and other anticonvulsants. In: Haddad L and Winchester J, eds. Clinical management of poisoning and drug overdose, 2nd ed. Philadelphia: W B Saunders, 1990:877–893.

    Google Scholar 

  9. Klasco RK, ed. DrugPoints® System. Thomson MICROMEDEX, Greenwood Village, CO.

  10. Burckart G, Ternullo S. Management of anticonvulsant overdoses. Clin Toxicol Consult 2;1980:88–99.

    Google Scholar 

  11. Larsen JR, Larsen LS. Clinical features and management of poisoning duetophenytoin. Med Toxicol Adverse Drug Exp 1989;4:229–245.

    PubMed  CAS  Google Scholar 

  12. Craig S. Phenytoin overdose complicated by prolonged intoxication and residual neurological deficits. Emerg Med Aust 2004;16:361–655.

    Article  Google Scholar 

  13. Black J, Hannaman T, Malone C. The relationship of serum albumin level to phenytoin toxicity. J Clin Pharmacol 1987;27:249–250.

    PubMed  CAS  Google Scholar 

  14. Chaikin P, Adir J. Unusual absorption profile of phenytoin in a massive overdose case. J Clin Pharmacol 1987;27:70–73.

    Article  PubMed  CAS  Google Scholar 

  15. Opheim KE, Raisys VA. Therapeutic drug monitoring in pediatric acute drug intoxications. Ther Drug Monit 1985;7:148–158.

    Article  PubMed  CAS  Google Scholar 

  16. Kugler AR, Knapp LE, Eldon MA. Rapid attainment of therapeutic phenytoin concentrations following administration of loading doses of fosphenytoin: a meta-analysis. Neurology 1996;46:A176.

    Google Scholar 

  17. Seger D. Anticonvulsant medications. In: Dart RC, Caravati EM, McGuigan MA et al., eds. Medical toxicology, 3rd ed. Philadelphia, Lippincott Williams & Wilkins, 2004;789–804.

    Google Scholar 

  18. Sweetman S, ed. Martindale: the complete drug reference, London: Pharmaceutical Press. Electronic version. Thomson MICROMEDEX, Greenwood Village, CO.

  19. Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Phrmacogenomics J. 2001;1:204–210.

    CAS  Google Scholar 

  20. Citerio G, Nobili A, Airoldi L, et al. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. Neurology 2003 60:1395–1396.

    PubMed  CAS  Google Scholar 

  21. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenyltoin. Pharmacogenetics 2001;11:803–808.

    Article  PubMed  CAS  Google Scholar 

  22. Brandolese R, Scordo MG, Spina E, et al. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70:391–394.

    PubMed  CAS  Google Scholar 

  23. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001;11:287–291.

    Article  PubMed  Google Scholar 

  24. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuschi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Moniot 2000;22:230–232.

    Article  CAS  Google Scholar 

  25. Birkett DJ. Non-linear Pharmacokinetics. Aust Prescr 1994;17:36–38.

    Google Scholar 

  26. Abe K, Okano M, Sasaki H. Phenytoin elimination kinetics in two children with drug intoxication. Eur J Paediatr 1980;135:69–71.

    Article  CAS  Google Scholar 

  27. Chua HC, Venketasubramanian N, Tjia H, Chan SP. Elimination of phenytoin in toxic overdose. Clin Neurol Neurosurg 2000;102:6–8.

    Article  PubMed  CAS  Google Scholar 

  28. Presutti M, Pollet L, Stordeur JM, Bruder N, Gouin F. [Acute poisoning with phenytoin caused by an error in the administration of fosphenytoin (Prodilantin)]. Ann Fr Anesth Reanim 2000;19: 688–690.

    PubMed  CAS  Google Scholar 

  29. Klasco RK, ed. Poisindex® Managements: Phenytoin. Thomson MICROMEDEX, Greenwood Village, CO.

  30. Garrettson LK, Jusko WJ. Diphenylhydantoin elimination kinetics in overdosed children. Clin Pharmacol Ther 1974;17:481–491.

    Google Scholar 

  31. Herberg KP. Inadvertent chronic diphenylhydantoin intoxication in a teenage girl. J South Carolina Med Assoc 1972;68:350–353.

    CAS  Google Scholar 

  32. Hopkins JJ, Rooney JC. Phenytoin intoxication in childhood due to incorrect prescribing, dispensing and administration of suspensions. MJA 1969;2:278–279.

    PubMed  CAS  Google Scholar 

  33. Bochner F, Hopper JH, Tyrer JH. Factors involved in an outbreak of phenytoin intoxication. J Neurol Sci 1972;16:481–487.

    Article  PubMed  CAS  Google Scholar 

  34. Tyrer JH, Eadie MJ, Sutherlands JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970;4:271–273.

    PubMed  CAS  Google Scholar 

  35. Braunwald E. Edema. Harrison’s principles of internal medicine, 13th ed. New York, McGraw-Hill, 1994:185–186.

    Google Scholar 

  36. Rossi S, et al., eds. Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd., 2000.

    Google Scholar 

  37. Prescribing information: Dilantin. In: MIMS full prescribing information. MIMS Online 2003. MIMS Australia Pty Ltd. 2003.

  38. Cachat F, Tufro A. Phenytoin/isradipine interaction causing severe neurologic toxicity. Ann Pharmacother 2002;36:1399–1402.

    Article  PubMed  Google Scholar 

  39. Shin JG, Park JY, Kim MJ, et al. Inhibitory effects of tricyclic anti-depressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002;30:1102–1107.

    Article  PubMed  CAS  Google Scholar 

  40. Mamiya K, Kojima K, Yukawa E, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 2001;23:75–77.

    Article  PubMed  CAS  Google Scholar 

  41. Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenyltoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 1997;17:107–109.

    Article  PubMed  CAS  Google Scholar 

  42. Brickell K, Porter D, Thompson P. Phenytoin toxicity due to fluoropyrimidines (5FU / capecitabine): three case reports. Br J Cancer 2003;89:615–616.

    Article  PubMed  CAS  Google Scholar 

  43. Buckley N, Dawson A, Whyte I, eds. HyperTox© 2004. MediTox Pty Ltd, NSW. 2004.

    Google Scholar 

  44. Eadie MJ. Phenytion. In: Shorvon SD, Fish DR, Peruvva E, Dodson WE. The treatment of epilepsy, 2nd ed. 2004. Malden, MA: Blackwell Science, 475–481.

    Google Scholar 

  45. Katz AA, Hoffman RS, Silverman RA. Phenytoin toxicity from smoking crack cocaine adulterated with phenytoin. Ann Emerg Med 1993;22:1485–1487.

    Article  PubMed  CAS  Google Scholar 

  46. Lau KK, Lai CK, Chan AW. Phenytoin poisoning after using Chinese proprietary medicines. Hum Exp Toxicol 2000;19:385–386.

    Article  PubMed  CAS  Google Scholar 

  47. Kearney TE. Phenytoin poisoning. In: Harwood-Nuss A, Wolfson AB, Linden CH et al., eds. The clinical practice of emergency medicine. Lippincott Williams & Wilkins, 2001.

  48. Osborn, H. Phenytoin and fosphenytoin toxicity. In: Tintinalli JE, Kelen GD, Stapczynski JS, eds. Emergency medicine: a comprehensive study guide, 6th ed. New York. Mc-Graw Hill, 2004:1117–1121.

    Google Scholar 

  49. Curtis DL, Piibe R, Ellenhorn MJ, Wasserberger J, Ordog G. Phenytion toxicity: a review of 94 cases. Vet Hum Toxicol 1989;31:164–165.

    PubMed  CAS  Google Scholar 

  50. Pedreira Vazquez I, Outeda Macias M, Martin Herranz I. Phenytoin: paradoxical toxicity; a discussion of 4 cases. Farm Hosp 2003;27:386–390.

    PubMed  CAS  Google Scholar 

  51. Merlo Gonzalez VE, Arbol Linde F, Rodriguez J, Lopez Onega P. Ventricular fibrillation during intravenous administration of phenytoin. Ann Med Intern 2002;19:158–159.

    CAS  Google Scholar 

  52. DeToledo JC, Iowe MR, Rabinstein A, Willaviza N. Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin. Epilepsia 2001;42:288.

    Article  PubMed  CAS  Google Scholar 

  53. Evers ML, Izhar A, Aqil A. Cardiac monitoring after phenytoin overdose. Heart Lung 1997;26:325–328.

    Article  PubMed  CAS  Google Scholar 

  54. Magadle R, Weiner P, Waizman J. Atrioventricular junctional arrhythmia due to oral phenytoin intoxication. Harefuah 1999;136:446–448, 514.

    PubMed  CAS  Google Scholar 

  55. O’Brien TJ, Cascino D, So EL, Hanna DR. Incidence and clinical consequences of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology 1998;51:1034–1039.

    PubMed  CAS  Google Scholar 

  56. Sintenie JB, Tuinebreijer WE, Kreis RW, Breederveld RS. Digital gangrene after accidental intra-arterial injection of phenytoin. Eur J Surg 1992;158:315–316.

    PubMed  CAS  Google Scholar 

  57. McLean CR, Cheng KS, Clifton MA. Fatal case of accidental intraarterial phenytoin injection. Eur J Vasc Endovasc Surg 2002;23:378–379.

    Article  PubMed  CAS  Google Scholar 

  58. Alioglu Z, Sari A, Velioglu SK, et al. Cerebellar atrophy following acute phenytoin intoxication. J Neuroradiol 2000;27:52–55.

    PubMed  CAS  Google Scholar 

  59. Zuin DR, Neme R, Porta L, Vera J, Lopez OL. Acute cerebellar atrophy caused by diphenylhydantoin intoxication resulting from drug interaction. Rev Neurol 2003;36:195–196.

    Article  PubMed  CAS  Google Scholar 

  60. Masur H, Fahrendorf G, Oberwittler C, Reuther G. Cerebellar atrophy following acute intoxication with phenytoin. Neurology 1990;40:1800–1801.

    PubMed  CAS  Google Scholar 

  61. Lindvall O, Nilsson B. Cerebellar atrophy following phenytoin intoxication. Ann Neurol. 1984;16:258–260.

    Article  PubMed  CAS  Google Scholar 

  62. Luef G, Marosi M, Felber S, Birbamer G, Aichner F, Bauer G. Cerebellar atrophy and phenytoin poisoning. An MR study. Nervenarzt 1993;64:548–551.

    PubMed  CAS  Google Scholar 

  63. Tichner JB, Enselberg CD. Suicidal dilantin (sodium diphenylhydantoin) poisoning: a case report. N Engl J Med 1951;245:723–725.

    Article  PubMed  CAS  Google Scholar 

  64. Petty CS, Muelling RJ, Sindell HW. Accidental, fatal poisoning with diphenylhydantoin (Dilantin). J Forensic Sci 1957;2:279–286.

    CAS  Google Scholar 

  65. Laubscher FA. Fatal diphenylhydantoin poisoning: a case report. JAMA 1966;198:1120–1121.

    Article  PubMed  CAS  Google Scholar 

  66. Delahunt B, George P, Gillis D, et al. RCPA Manual. Royal College of Pathologists of Australasia. Sydney.

  67. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002;24:379–385.

    Article  PubMed  CAS  Google Scholar 

  68. Burt M, Anderson DC, Kloss J, Apple FS. Evidence-based implementation of free phenytoin therapeutic drug monitoring. Clin Chem 2000 46:1132–1135.

    PubMed  CAS  Google Scholar 

  69. Braitberg G, Kerr F. Central nervous system drugs. In: Cameron P, Jelinek G, Kelly, AM, Murray L, Brown AFT, Heyworth J, eds. Textbook of adult emergency medicine, 2nd ed. London: Churchill Livingstone, 2004:817.

    Google Scholar 

  70. Krenzelok EP, McGuigan M, Lheur P. Position statement: ipecac syrup. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997;35:669–709.

    Google Scholar 

  71. Vale JA. Poistion statement: gastric lavage. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Toxicol Clin Toxicol 1997;35:711–719.

    CAS  Google Scholar 

  72. Murray L. General principles in the management of drug overdose. In: Cameron P, Jelinek G, Kelly, AM, Murray L, Brown AFT, Heyworth J, eds. Textbook of adult emergency medicine, 2nd ed. London: Churchill Livingstone, 2004:790–796.

    Google Scholar 

  73. Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Toxicol Clin Toxicol 1997;35:721–741.

    CAS  Google Scholar 

  74. Barceloux D, McGuigan M, Hartigan-Go K. Position statement: cathartics. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Toxicol Clin Toxicol 1997;35:743–752.

    Article  CAS  Google Scholar 

  75. Kirshenbaum LA, Mathew SC, Sitar DS, Tenenbein M. Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharm Ther 1989;46:264–271.

    Article  CAS  Google Scholar 

  76. Smith SW, Ling LJ, Halstenson CE. Whole-bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med. 1991;20:536–539.

    Article  PubMed  CAS  Google Scholar 

  77. Tenenbein M. Position statement: whole bowel irrigation. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Toxicol Clin Toxicol 1997;35:743–752.

    Google Scholar 

  78. Arimori K, Nakano M. The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats. J Pharmacobiodyn 1987;10:157–165.

    PubMed  CAS  Google Scholar 

  79. Mauro LS, Mauro VF, Brown DL, Somani P. Enhancement of phenytoin elimination by multiple-dose activated charcoal. Ann Emerg Med. 1987;16:1132–1135.

    Article  PubMed  CAS  Google Scholar 

  80. Rowden AM, Spoor JE, Bertino JS Jr. The effect of activated charcoal on phenytoin pharmacokinetics. Ann Emerg Med. 1990;19:1144–1147.

    Article  PubMed  CAS  Google Scholar 

  81. Levy G. Gastrointestinal clearance of drugs with activated charcoal. N Engl J Med 1982;307:676–678.

    Article  PubMed  CAS  Google Scholar 

  82. Ros S, Black L. Multiple-dose activated charcoal in management of phenytoin overdose. Pediatr Emerg Care 1989;5:169–170.

    Article  PubMed  CAS  Google Scholar 

  83. Howard CE, Roberts RS, Ely DS, Moye RA. Use of multiple-dose activated charcoal in phenytoin toxicity. Ann Pharmacother 1994;28:201–203.

    PubMed  CAS  Google Scholar 

  84. Weichbrodt GD, Elliott, DP. Treatment of phenytoin toxicity with repeated doses of activated charcoal. Ann Emerg Med 1987;16:1387–1389.

    Article  PubMed  CAS  Google Scholar 

  85. Dolgin JG, Nix DE, Sanchez J, Watson WA. Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning — report of two paediatric cases. DICP 1991;25:646–649.

    PubMed  CAS  Google Scholar 

  86. Dunn R. Toxicology. In: Dunn R, Dilley S, Brookes J, Leach D, Maclean A, Rogers I, eds. The emergency medicine manual, 3rd ed. Tennyson, South Australia: Venom Publishing, 2003:720–721.

    Google Scholar 

  87. Eroglu A, Kucuktulu U, Erciyes N, Turgutlap H. Multiple dose-activated charcoal as a cause of acute appendicitis. J Toxicol Clin Toxicol 2003;41:71–73.

    Article  PubMed  Google Scholar 

  88. Gomez HF, Brent JA, Munoz DC, 4th, et al. Charcoal stercolith with intestinal perforation in a patient treated for amitriptyline ingestion. J Emerg Med. 1994; 12:57–60.

    Article  PubMed  CAS  Google Scholar 

  89. Goulbourne KB, Cisek JE. Small-bowel obstruction secondary to activated charcoal and adhesions. Ann Emerg Med. 1994;24:108–110.

    PubMed  CAS  Google Scholar 

  90. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position statement and practice guidelines on the use of multiple-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol 1999;37:731–751.

    Article  Google Scholar 

  91. Baehler RW, Work J, Smith W, Dominic JA. Charcoal hemoperfusion in the therapy for methsuximide and phenytoin overdose. Arch Intern Med 1980;140:1466–1468.

    Article  PubMed  CAS  Google Scholar 

  92. Kawasaki C, Nishi R, Uekihara S, Hayono S, Otagiri M. Charcoal haemoperfusion in the treatment of phenytoin overdose. Am J Kidney Dis 2000;25:323–326.

    Google Scholar 

  93. Kanayama Y, Itakura Y, Iwasaki M, et al. Changes in phenytoin concentrations in blood and cerebrospinal fluid caused by direct haemoperfusion in a patient intoxicated with phenytoin. Ther Apher 1998;2:74–77.

    PubMed  CAS  Google Scholar 

  94. Reiter K, Bordoni V, Dall’Olio G, et al. In vitro removal of therapeutic drugs with a novel adsorbent system. Blood Purif 2002;20:380–388.

    Article  PubMed  CAS  Google Scholar 

  95. Lindahl S, Westerling D. Detoxification with peritoneal dialysis and blood exchange after diphenylhydantoin intoxication. Acta Paediatr Scand 1982;71:665–666.

    PubMed  CAS  Google Scholar 

  96. Czajka PA, Anderson WH, Christoph RA, Banner W Jr. A pharmacokinetic evaluation of peritoneal dialysis for phenytoin intoxication. J Clin Pharmacol 1980;20:565–569.

    PubMed  CAS  Google Scholar 

  97. Narcy P, Zorza G, Taburet AM, Mersch JM, Devictor D, Huault G. Severe poisoning with intravenous phenytoin in the newborn. Value of peritoneal dialysis. Arch Fr Pediatr. 1990;47:591–593.

    PubMed  CAS  Google Scholar 

  98. Adler DS, Martin E, Gambertoglio JG, Tozer TN, Spire JP. Hemodialysis of phenytoin in a uremic patient. Clin Pharmacol Ther 1975;18:65–69.

    PubMed  CAS  Google Scholar 

  99. Martin E, Gambertoglio JG, Adler DS, Tozer TN, Roman LA, Grausz H. Removal of phenytoin by hemodialysis in uremic patients. JAMA 1977;238:1750–1753.

    Article  PubMed  CAS  Google Scholar 

  100. Dasgupta A, Abu-Alfa A. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uraemia treated with haemodialysis: role of uraemic compounds. Am J Clin Pathol 1992;98:19–25.

    PubMed  CAS  Google Scholar 

  101. Frenchie D, Bastani B. Significant removal of phenytoin during high flux dialysis with cellulose triacetate dialyzer. Nephrol Dial Transplant 1998;13:817–818.

    PubMed  CAS  Google Scholar 

  102. Rose R, Cisek J, and Mickell J. Fosphenytoin-induced bradyasystole arrest in an infant treated with charcoal haemofiltration. 1998 North American Congress of Clinical Toxicology, Orlando FL. J Tox Clin Toxicol 1998;36:473.

    Google Scholar 

  103. Larsen LS, Sterrett JR, Whitehead B, Marcus SM. Adjunctive therapy of phenytoin overdose—a case report using plasmaphoresis. J Toxicol Clin Toxicol 1986;24:37–49.

    Article  PubMed  CAS  Google Scholar 

  104. Brown-Molnar CS, Bauer LA, Horn JR. Phenytoin removal by plasmapheresis in renal insufficiency. Am J Nephrol 1986;6:302–306.

    PubMed  CAS  Google Scholar 

  105. Silberstein LE, Shaw LM. Effect of plasma exchange on phenytoin plasma concentration. Ther Drug Monit 1986;8:172–176.

    Article  PubMed  CAS  Google Scholar 

  106. White RL, Garnett WR, Allen JH, Kline BJ, Sharp DE. Phenytoin removal during plasma exchange. J Clin Apheresis 1987;3:147–150.

    Article  PubMed  CAS  Google Scholar 

  107. Sen S, Ratnaraj N, Davies N, et al. Treatment of phenytoin toxicity by the Molecular Adsorbents Recirculating System (MARS). Epilepsia 2003;44:265–267.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Monash Medical Centre, Locked Bag 29, 3169, Clayton, Victoria, Australia

    Simon Craig (Emergency Registrar)

Authors
  1. Simon Craig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon Craig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Craig, S. Phenytoin poisoning. Neurocrit Care 3, 161–170 (2005). https://doi.org/10.1385/NCC:3:2:161

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/NCC:3:2:161

Key Words

Search

Navigation